Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Duloxetine has FDA approval for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain (including osteoarthritis and chronic low back pain). This broad approval profile reflects duloxetine's ability to address both the emotional and physical dimensions of suffering.

Off-label uses include stress urinary incontinence (approved in Europe), chemotherapy-induced peripheral neuropathy, and as adjunct treatment in bipolar depression or treatment-resistant depression.

How It Works

Duloxetine inhibits both the serotonin transporter (SERT) and the norepinephrine transporter (NET), increasing synaptic availability of both neurotransmitters. This dual mechanism affects mood, anxiety, and — crucially — pain modulation. Norepinephrine plays a key role in activating descending inhibitory pain pathways from the brainstem to the spinal cord, which suppress pain signals before they reach conscious awareness.

Unlike venlafaxine, which only achieves significant norepinephrine reuptake inhibition at higher concentrations, duloxetine demonstrates balanced serotonin and norepinephrine inhibition across its therapeutic range. This pharmacological balance may explain its efficacy in pain conditions at relatively lower concentrations.

Duloxetine is primarily metabolized in the liver by CYP1A2 and CYP2D6. Its delayed-release capsule formulation protects the drug from acid degradation in the stomach, allowing intestinal absorption.

Side Effects

Common

• Nausea (most common, especially early; taking with food reduces risk)
• Dry mouth
• Fatigue or somnolence
• Constipation
• Dizziness
• Increased sweating
• Decreased appetite
• Sexual dysfunction (reduced libido, delayed ejaculation)

Serious

• Hepatotoxicity — rare but reported; avoid in patients with substantial alcohol use or chronic liver disease
• Serotonin syndrome — risk elevated with concurrent serotonergic agents or MAOIs
• Hypertension — norepinephrine activity can raise blood pressure; monitor regularly
• Suicidal ideation — black box warning in patients under 25
• Discontinuation syndrome — among the most severe of any antidepressant; brain zaps, dizziness, nausea, irritability on abrupt cessation
• Hyponatremia — SIADH-mediated; particularly in elderly patients
• Abnormal bleeding — reduced platelet aggregation increases bleeding risk

Drug Interactions

Drug / Class	Interaction	Clinical Significance
MAO Inhibitors	Severe, potentially fatal serotonin syndrome	Contraindicated — 14-day washout required
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)	Significant increase in duloxetine plasma levels; toxicity risk	High — contraindicated with fluvoxamine
CYP2D6 substrates (TCAs, metoprolol, antipsychotics)	Duloxetine inhibits CYP2D6, elevating co-drug concentrations	Moderate–High — monitor and adjust doses
Thioridazine	Increased thioridazine plasma levels; serious cardiac arrhythmia risk	Contraindicated
NSAIDs / Warfarin	Increased bleeding risk through platelet inhibition and possible warfarin effect potentiation	Moderate — consider GI protection; monitor INR
Alcohol	Increased hepatotoxicity risk; CNS depression	High — avoid alcohol during treatment
Triptans / Tramadol	Enhanced serotonergic effects; serotonin syndrome risk	Moderate — monitor closely

Warnings & Contraindications

Contraindications: Concurrent MAO inhibitor use. Uncontrolled narrow-angle glaucoma. Use with thioridazine or fluvoxamine. Known hypersensitivity to duloxetine.

Hepatotoxicity: Duloxetine should be avoided in patients with significant alcohol use, pre-existing liver disease, or evidence of hepatic insufficiency, as rare but serious liver injury has been reported.

Discontinuation: Cymbalta has one of the most challenging discontinuation profiles among antidepressants. Always taper slowly under medical supervision. Abrupt discontinuation can cause severe "discontinuation syndrome" — sometimes called "Cymbalta discontinuation syndrome" — characterized by severe dizziness, nausea, sensory disturbances, and irritability.

Blood pressure: Noradrenergic activity may increase blood pressure. Blood pressure should be measured before initiating treatment and periodically during use.

Frequently Asked Questions

Can duloxetine be used for nerve pain without depression?

Yes. Duloxetine's FDA approvals for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain are independent of its antidepressant indication. Clinicians prescribe it for chronic pain in patients who do not have depression, based on its ability to strengthen descending pain inhibition pathways in the central nervous system.

Why is stopping duloxetine so difficult?

Duloxetine has a relatively short half-life (~12 hours) and affects both serotonin and norepinephrine systems. When stopped abruptly, the sudden loss of these effects produces a withdrawal-like discontinuation syndrome. Symptoms include dizziness, electric shock sensations, nausea, anxiety, and irritability. Slow tapering over weeks to months significantly reduces this risk.

Does duloxetine cause weight gain?

Duloxetine tends to be weight-neutral or associated with mild weight loss short-term. Long-term use may lead to modest weight gain in some patients, though the effect is generally less pronounced than with SSRIs such as paroxetine.

Is duloxetine better than SSRIs for anxiety?

Duloxetine is a guideline-recommended first-line treatment for generalized anxiety disorder and may have advantages for patients with significant somatic or physical anxiety symptoms, given its dual noradrenergic mechanism. However, head-to-head comparisons with SSRIs show broadly similar efficacy; tolerability and individual patient factors guide the choice.

→ SNRI Side Effects Guide → Depression Medications Guide → Chronic Pain Medications Guide